The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The pathway alteration load as a pan-cancer determinant of outcome of targeted therapies: Results from the Drug Rediscovery Protocol (DRUP).
 
Karlijn Verkerk
No Relationships to Disclose
 
Laurien Joanna Zeverijn
No Relationships to Disclose
 
Joris van de Haar
No Relationships to Disclose
 
Paul Roepman
No Relationships to Disclose
 
Birgit Geurts
No Relationships to Disclose
 
Ilse Anna Catharina Spiekman
No Relationships to Disclose
 
Vincent van der Noort
No Relationships to Disclose
 
Jade Maxime van Berge Henegouwen
No Relationships to Disclose
 
Louisa Rose Hoes
No Relationships to Disclose
 
Hanneke van der Wijngaart
No Relationships to Disclose
 
Anne M.L. Jansen
No Relationships to Disclose
 
Wendy W.J. de Leng
No Relationships to Disclose
 
Henk M.W. Verheul
No Relationships to Disclose
 
Hans Gelderblom
Research Funding - AmMax Bio (Inst); Deciphera (Inst); Ipsen (Inst); Novartis (Inst)
 
Emile E. Voest
Leadership - Mosaic Therapeutics; Sanofi
Stock and Other Ownership Interests - Mosaic Therapeutics; Sanofi
Consulting or Advisory Role - Biogeneration Ventures; InteRNA
Research Funding - astrazeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst)